SQUAWK/NEWS
Account
Theme
Account
Menu
Live NewsCategoriesequity

Femasys Inc. (FEMY) News

Follow Femasys Inc. (FEMY) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 10 public stories across 9 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.

Symbol FEMY Asset equity Sector Markets 90 days 6 Last 1.24 Updated Oct 14, 2026, 01:00 PM UTC Open live news feed Open FEMY chart & news
L Femasys doubles enrollment sites in FemBloc pivotal trial Femasys doubled the number of enrolling sites in its FINALE pivotal trial for non-surgical permanent birth control. EQUITY | Oct 14, 2026, 01:00 PM UTC L FEMY - Femasys Advances OB/GYN Expansion with Adoption of FemaSeed® Fertility Portfolio by Minnesota Women’s Care FEMY - Femasys Advances OB/GYN Expansion with Adoption of FemaSeed® Fertility Portfolio by Minnesota Women’s Care NEWS | Sep 15, 2026, 01:00 PM UTC L Femasys partners with CapexMD to expand FemaSeed patient access Femasys said its collaboration with CapexMD will provide dedicated patient financing for its FemaSeed fertility solutions across OB/GYN practices and fertility centers, aiming to reduce financial barriers to care. EQUITY | Sep 09, 2026, 01:03 PM UTC L FEMY partners with CapexMD to expand patient access Femasys partners with CapexMD to expand patient access to its FemaSeed fertility portfolio. EQUITY | Sep 09, 2026, 01:01 PM UTC L Femasys files SEC resale for up to 28,124,997 shares of common stock Femasys (FEMY) filed an SEC registration for the resale of up to 28,124,997 shares of common stock. REGULATION | Sep 03, 2026, 09:53 PM UTC L Femasys partners with UNC Health to expand FemaSeed fertility portfolio Femasys Partners with UNC Health to introduce its FemaSeed fertility portfolio across statewide OB/GYN care locations. EQUITY | Aug 26, 2026, 01:00 PM UTC M Femasys FDA approves modular PMA submission approach for FemBloc® Femasys announces FDA approval of a modular PMA submission approach for its FemBloc® device. REGULATION | Aug 19, 2026, 01:00 PM UTC L Femasys reports quarter ended June 30, 2026 financial results Femasys announces financial results for the quarter ended June 30, 2026 and provides a corporate update. EARNINGS | Aug 14, 2026, 08:05 PM UTC L FEMY Strengthens Patent Protection Femasys strengthens global patent protection for FemBloc with issued blended polymer patents EQUITY | Aug 12, 2026, 01:00 PM UTC L FEMY Regains Compliance Femasys regains compliance with Nasdaq listing requirements REGULATION | Jun 24, 2026, 01:00 PM UTC